drugset / Trial / NCT02091739

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

NCT02091739 ↗

Phase 3 Completed 184 enrolled Merz Pharmaceuticals GmbH
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of chronic troublesome sialorrhea that occurs as a result of various neurological conditions in adult subjects.

Timeline

Start
2014-04
Primary completion
2015-08
Completion
2016-11

Outcome

Met primary endpoint

registry analysis (superiority test); MP: Placebo vs MP: IncobotulinumtoxinA (Xeomin) (100 Units); p = 0.004; LS mean difference -0.09 (95% CI -0.15 to 0.03); MMRM NCT02091739 ↗

registry analysis (superiority test); MP: Placebo vs MP: IncobotulinumtoxinA (Xeomin) (100 Units); p = 0.002; LS mean difference 0.58 (95% CI 0.22 to 0.94); MMRM NCT02091739 ↗

paper Patients' Global Impression of Change Scale scores also improved at week 4, with a significant difference vs placebo in the incobotulinumtoxinA 100 U group (p = 0.002). PMID 30918101 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic 75 iu Other
Subject Botulinum toxin type A Protein / enzyme biologic 100 iu Other